Shalini Mulaparthi, MD
Medical Oncology · Lakeland, FLNPI 1427048537
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,401 of the $3,876 with a category attached, or 87.7%. It is spread thinly across 40 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,729, 4.3 times the $403 reported in 2019. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 153 payments — averaging $25.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$669
- Novartis$541
- Sanofi$322
- Johnson & Johnson$238
- Genentech USA, Inc.$229
- Gilead$171
- plus $2K from 34 others
Across 35 payments — averaging $3701.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$48K
- Amgen$44K
- Bristol Myers Squibb$20K
- Sanofi US Services Inc.$15K
- Helsinn Healthcare SA$2K
- E.r. Squibb & Sons, L.L.C.$750
What the payments were for
- Food & beverage$3,40188%
- Education$47512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 33 | $669 |
| Novartis | 21 | $541 |
| Sanofi | 14 | $322 |
| Johnson & Johnson | 8 | $238 |
| Genentech USA, Inc. | 6 | $229 |
| Gilead | 8 | $171 |
| Bristol Myers Squibb | 6 | $147 |
| Array Biopharma Inc | 6 | $147 |
| AstraZeneca | 1 | $117 |
| Daiichi Sankyo Inc. | 5 | $107 |
| Seagen Inc. | 1 | $100 |
| Incyte Corporation | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| GSK | 3 | $75 |
| Bayer | 3 | $69 |
| AVEO Pharmaceuticals, Inc. | 3 | $66 |
| Astellas Pharma US Inc | 3 | $59 |
| Sobi, Inc | 2 | $57 |
| Jazz Pharmaceuticals Inc. | 2 | $53 |
| AbbVie | 2 | $44 |
| Lilly USA, LLC | 2 | $42 |
| Stemline Therapeutics Inc. | 2 | $40 |
| Amgen | 2 | $31 |
| Verity Pharmaceuticals Inc. | 2 | $29 |
| ADC Therapeutics America, Inc. | 1 | $29 |
| Pharmaessentia USA Corporation | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Sandoz | 1 | $24 |
| Myriad Genetic Laboratories, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Spectrum Pharmaceuticals Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $16 |
| Smith+Nephew | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,876 in reported general payments places this provider in the 30th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 83 | $1,358,508 |
| Lenalidomide | 68 | $875,202 |
| OjjaaraMomelotinib Dihydrochloride | 31 | $870,923 |
| PomalystPomalidomide | 36 | $814,175 |
| IbrancePalbociclib | 40 | $642,661 |
| RevlimidLenalidomide | 36 | $620,614 |
| JakafiRuxolitinib Phosphate | 32 | $426,605 |
| XtandiEnzalutamide | 37 | $415,258 |
| CabometyxCabozantinib S-Malate | 14 | $339,270 |
| VenclextaVenetoclax | 29 | $325,659 |
| OnuregAzacitidine | 12 | $303,454 |
| CalquenceAcalabrutinib Maleate | 19 | $284,462 |
| JaypircaPirtobrutinib | 11 | $247,398 |
| TagrissoOsimertinib Mesylate | 12 | $201,518 |
| TasignaNilotinib Hcl | 11 | $157,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg | $25 | $1,117,62948 claims |
| GSKOjjaara | $75 | $870,92331 claims |
| PfizerIbrance, Eliquis | $669 | $776,247206 claims |
| Bristol Myers SquibbRevlimid | $147 | $620,61436 claims |
| AstraZenecaCalquence, Tagrisso | $117 | $485,98031 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $59 | $428,78059 claims |
| Incyte CorporationJakafi | $100 | $426,60532 claims |
| AbbVieVenclexta, Creon | $44 | $356,23548 claims |
| Exelixis Inc.Cabometyx | $16 | $339,27014 claims |
| Lilly USA, LLCJaypirca | $42 | $247,39811 claims |
| NovartisTasigna | $541 | $157,96211 claims |
| Johnson & JohnsonXarelto | $238 | $70,78574 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Lakeland
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.